Last reviewed · How we verify
Omeprazol
At a glance
| Generic name | Omeprazol |
|---|---|
| Also known as | Prilosec, Losec |
| Sponsor | RenJi Hospital |
| Target | ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Approved indications
- Duodenal Ulcer due to H. Pylori
- Duodenal ulcer disease
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastric ulcer
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Pathological Gastric Hypersecretory Condition
- Peptic reflux disease
- Peptic ulcer
- Reduction of risk of upper gastrointestinal bleeding
- Zollinger-Ellison syndrome
Common side effects
Key clinical trials
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants (PHASE1)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing (PHASE4)
- Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (PHASE2)
- OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers (PHASE4)
- PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers (PHASE4)
- Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |